218 related articles for article (PubMed ID: 21453661)
1. End points for cisplatin ototoxicity.
Qureshy K; Blakley B; Alsaleh S; Quddusi T; Berard S
J Otolaryngol Head Neck Surg; 2011 Feb; 40 Suppl 1():S45-8. PubMed ID: 21453661
[TBL] [Abstract][Full Text] [Related]
2. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals.
Sockalingam R; Freeman S; Cherny TL; Sohmer H
Am J Otol; 2000 Jul; 21(4):521-7. PubMed ID: 10912698
[TBL] [Abstract][Full Text] [Related]
3. Ototoxic drugs: difference in sensitivity between mice and guinea pigs.
Poirrier AL; Van den Ackerveken P; Kim TS; Vandenbosch R; Nguyen L; Lefebvre PP; Malgrange B
Toxicol Lett; 2010 Mar; 193(1):41-9. PubMed ID: 20015469
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
5. Recovery of hearing following cisplatin ototoxicity in the guinea pig.
O'Leary SJ; Klis SF
Anticancer Res; 2002; 22(3):1525-8. PubMed ID: 12168832
[TBL] [Abstract][Full Text] [Related]
6. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
7. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
8. Intratympanic dexamethasone to prevent cisplatin ototoxicity: a guinea pig model.
Murphy D; Daniel SJ
Otolaryngol Head Neck Surg; 2011 Sep; 145(3):452-7. PubMed ID: 21521888
[TBL] [Abstract][Full Text] [Related]
9. Friend or foe? Effect of oral resveratrol on cisplatin ototoxicity.
Olgun Y; Kırkım G; Kolatan E; Kıray M; Bagrıyanık A; Olgun A; Kızmazoglu DC; Ellıdokuz H; Serbetcıoglu B; Altun Z; Aktas S; Yılmaz O; Günerı EA
Laryngoscope; 2014 Mar; 124(3):760-6. PubMed ID: 23900991
[TBL] [Abstract][Full Text] [Related]
10. Differences in Ototoxicity across Species.
Blakley BW; Hochman J; Wellman M; Gooi A; Hussain AE
J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):700-3. PubMed ID: 19128679
[TBL] [Abstract][Full Text] [Related]
11. A clinically derived guinea pig dosing model of cisplatin ototoxicity.
Stanford JK; Bosworth NA; Morgan DS; Chen T; Spankovich C
Hear Res; 2021 May; 404():108202. PubMed ID: 33621791
[TBL] [Abstract][Full Text] [Related]
12. Protective role of resveratrol against cisplatin induced ototoxicity in guinea pigs.
Yumusakhuylu AC; Yazici M; Sari M; Binnetoglu A; Kosemihal E; Akdas F; Sirvanci S; Yuksel M; Uneri C; Tutkun A
Int J Pediatr Otorhinolaryngol; 2012 Mar; 76(3):404-8. PubMed ID: 22261612
[TBL] [Abstract][Full Text] [Related]
13. [Reduced nutritional status enhances ototoxicity].
Lautermann J; Schacht J
Laryngorhinootologie; 1995 Dec; 74(12):724-7. PubMed ID: 8579670
[TBL] [Abstract][Full Text] [Related]
14. Does intracochlear brain-derived nerve growth factor improve auditory brainstem click thresholds in sensorineural hearing loss?
Meen E; Blakley B; Quddusi T
J Otolaryngol Head Neck Surg; 2010 Jun; 39(3):232-5. PubMed ID: 20470666
[TBL] [Abstract][Full Text] [Related]
15. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig.
Ekborn A; Lindberg A; Laurell G; Wallin I; Eksborg S; Ehrsson H
Cancer Chemother Pharmacol; 2003 Jan; 51(1):36-42. PubMed ID: 12497204
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
17. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
18. [Electrophysiological evaluation of the hearing function following cisplatin administration].
Bogomol'skiĭ MR; D'iakonova IN; Rakhmanova IV; Sapozhnikov IaM; Stakhovskaia OR; Tikhomirov AM
Vestn Otorinolaringol; 2010; (3):24-6. PubMed ID: 20559247
[TBL] [Abstract][Full Text] [Related]
19. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
20. Can intratympanic dexamethasone protect against cisplatin ototoxicity in mice with age-related hearing loss?
Parham K
Otolaryngol Head Neck Surg; 2011 Oct; 145(4):635-40. PubMed ID: 21572077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
